Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics, Inc. director John Maraganore received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. Following this award, he holds 15,200 options directly.
The options vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders, subject to his continued service on that vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Rapport Therapeutics director Robert J. Perez received a grant of stock options for 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036.
The shares underlying this option vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders of Rapport Therapeutics, subject to his continued service on that vesting date. Following this grant, he holds 15,200 derivative securities directly.
Rapport Therapeutics, Inc. director Steven M. Paul received a grant of stock options covering 15,200 shares of common stock. The options carry an exercise price of $35.21 per share and expire on June 10, 2036.
According to the terms, the 15,200 underlying shares will vest on the earlier of June 10, 2027 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through that vesting date. Following this grant, he holds 15,200 stock options directly.
Rapport Therapeutics director Paul M. Silva received a grant of stock options as equity compensation. The award covers 15,200 options to buy common stock at an exercise price of $35.21 per share, expiring on June 10, 2036. These options vest on the earlier of June 10, 2027 or the next Annual Meeting of Stockholders, subject to his continued service.
Rapport Therapeutics director James Healy received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036.
The 15,200 underlying shares vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics' next Annual Meeting of Stockholders, as long as Healy continues serving the company through that vesting date. After this award, he holds 15,200 derivative securities from this grant.
Rapport Therapeutics, Inc. director Reid M. Huber received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. These options vest on the earlier of June 10, 2027 or the next Annual Meeting of Stockholders, subject to his continued service.
Rapport Therapeutics director Wendy B. Young received a grant of stock options covering 15,200 shares of Common Stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. Following this award, she holds 15,200 options directly.
The 15,200 underlying shares will vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics’ next Annual Meeting of Stockholders, as long as she continues to serve with the company through that vesting date.
Rapport Therapeutics director Ramiro Sanchez received a grant of stock options covering 15,200 shares of Common Stock of Rapport Therapeutics, Inc. The options have an exercise price of $35.21 per share and expire on June 10, 2036.
The 15,200 option shares vest on the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders, subject to Sanchez’s continued service. Following this award, he holds 15,200 derivative securities directly.
Rapport Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on board elections and auditor ratification. As of the April 14, 2026 record date, 47,807,623 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class II directors to serve until the 2029 annual meeting: James Healy, M.D., Ph.D. (41,762,713 votes for and 587,163 withheld), Robert J. Perez (37,592,089 for and 4,757,787 withheld), and Raymond Sanchez, M.D. (41,754,131 for and 595,745 withheld), each with 1,983,035 broker non-votes. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 44,255,547 votes for, 57,445 against, and 19,919 abstentions.
Third Rock Ventures funds reported a small sale of Rapport Therapeutics stock. Third Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. common stock on May 26, 2026 in open-market transactions at a weighted average price of $40.047 per share, under a pre-arranged Rule 10b5-1 trading plan dated November 21, 2025.
After the sale, Third Rock Ventures V, L.P. directly held 6,280,525 shares of common stock. A related fund, Third Rock Ventures VI, L.P., is reported with 969,218 shares held indirectly, reflecting a continuing, sizeable ownership position across these affiliated investment entities.